Redmond, CharleneBusby, JohnMansur, Adel HPatel, MiteshPatel, Pujan HPfeffer, Paul EHeaney, Liam GRupani, Hitasha2025-12-022025-12-022025-10-22Redmond C, Busby J, Mansur AH, Patel M, Patel PH, Pfeffer PE, Heaney LG, Rupani H. Long term clinical remission on biologics: an analysis of real-worl data from the UK severe asthma registry. J Allergy Clin Immunol Pract. 2025 Oct 22:S2213-2198(25)00962-6. doi: 10.1016/j.jaip.2025.10.011. Epub ahead of print.2213-21982213-220110.1016/j.jaip.2025.10.01141135851S2213-2198(25)00962-6https://westmid.openrepository.com/handle/20.500.14200/9155BACKGROUND: Clinical remission on biologics is an achievable goal for patients with severe asthma (SA). Most reports present short term follow-up, include small cohort sizes or present data on patients included in clinical trials. OBJECTIVE: This study evaluates clinical remission rates in a real-world cohort of patients over the course of up to 4 years on different biologics and include those who switched biologic during this period. We also assess barriers and predictors of remission. METHODS: Retrospective study of 525 patients in the UK SA registry who were initiated on a biologic between January 2015 and May 2022. Clinical remission was assessed at two time points: first review (9-24 months) and long-term review (30-48 months), and defined as controlled asthma (ACQ6<1.5), no exacerbations in the preceding 12 months and no maintenance oral corticosteroid use. RESULTS: Clinical remission was achieved in 25.1% at first review, increasing to 32.1% at long-term reivew. This improvement occurred regardless of biologic switching. Among those in remission at first review, 69.7% remained in remission at long-term review while 45.6% of those in long-term remission had not been in remission at first review. Higher symptoms burden and presence of anxiety/depression was negatively associated with achieving long-term remission. Advanced age at baseline and the presence of nasal polyps increased likelihood of long-term remission. CONCLUSION: In this large real-world cohort of patients with SA, there is a progressive increase in remission rates over 4 years, which is influenced by the presence of comorbidities but is largely independent of biologic switching.enCopyright © 2025. Published by Elsevier Inc.AsthmaBiological productsArticle